tirzepatide gyógyszer Overview Tirzepatide Reduces Food Intake and
Description
For the glucose-lowering indication, these are categorised as: Very common (affecting one in every 10 people): Nausea, diarrhoea, hypoglycaemia when used with a sulfonylurea or insulin

Tirzepatide is not indicated for type 1 diabetes management

A 2022 study found that about 5% to 6% of people taking tirzepatide (5 to 15 mg) had hair loss or thinning

These are actual patients from our San Antonio clinic

Cardiol Rev 101097 Thomsen M, Holst JJ, Molander A et al (2019) Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring Vervet monkeys
